![MEHTA — Rewarding Relationships]

08th - 12th June, 2026

WEALTH WEEKLY

Weekly Alerts You Can Use!

Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	23367	22900	23651	23685	24956	23045-23599	Sell at CMP. Targets at 22900/22650. Aggressive targets at 22350-22400. Stop at 23651
BANK NIFTY	54496	52700	55000	54447	56990	52900-54900	Sell at CMP. Targets 52922/51651. Aggressive targets at 50900. Stop at 55300.

Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
FORTIS	969	839	1150	908	927	Positive	**Fortis Healthcare** is a high-quality healthcare play riding on India's long-term healthcare demand story. The combination of hospitals, diagnostics, expanding capacity, and a strong national brand positions the company well for sustained earnings growth over the next several years. The Gyan Mantra is that "Healthcare is not a cyclical story; it is a structural story. The real winners are often those who keep adding beds, patients, and trust. Fortis Healthcare reported a robust Q4 FY26, posting a 44.2% year-on-year surge in net profit to ₹271.2 crore and an 17.8% increase in consolidated revenue to ₹2,364.7 crore. Strong double-digit growth was largely driven by sustained volume growth in its core hospital business and expansion into high-end clinical specialties. **Look to buy at CMP, and on dips between 880-900 zone, targeting 993/1031, and then aggressive targets at psychological 1150 mark. Stop below 839. Holding Period 9-12 Months.**

Fortis Healthcare	BUY
CMP	969
Target Price	1150
Stop	839
52 Week H/L	1105/741
P/E	69.10
EPS (TTM)	3.05
Promoter Holding/FIIs/DIIs/FIIs/Public	31.17%/25.98%/31.35%/11.5%
Book Value	131
Market Cap (INR)	73129

Fortis Healthcare: Technically Massive Breakout Play on Cards.

Fortis Healthcare is one of India's leading integrated healthcare service providers, operating across hospitals, diagnostics, and specialty care facilities. The company is backed by healthcare major IHH Healthcare and has established itself as one of the country's most recognized healthcare brands.

 # Key Highlights

Operates 36 healthcare facilities across 12 states and union territories in India. | Network of 6,000+ operational beds. | Supported by 17,900+ healthcare professionals. | Presence in diagnostics through 400+ diagnostic laboratories.

Strong footprint across key cities including Delhi NCR, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Hyderabad, Mohali, Jaipur, and Ludhiana.

Daily Chart of FORTIS :



 # Business Segments

1) Hospitals

Fortis operates multi-specialty and super-specialty hospitals offering advanced treatment in:

Cardiology & Cardiac Surgery | Oncology | Neurosciences | Orthopaedics | Organ Transplants | Gastroenterology | Critical Care | Renal Sciences

Hospital Business: Revenue rose 18.9% YoY to ₹2,023.2 crore. This was fueled by increased occupied bed days, strong traction in robotic surgeries, and higher specialty-led volumes.

 # Diagnostics

The company controls diagnostics business through its subsidiary Agilus Diagnostics (formerly SRL Diagnostics), one of India's largest diagnostic chains with presence in hundreds of cities and towns.

Diagnostics Business (SRL): Revenue increased 11.1% YoY to ₹387.3 crore, backed by a 5% volume growth and the addition of B2C/B2B customer touchpoints.

Competitive Strengths

1) Strong Brand Equity: Fortis is among the most trusted private healthcare brands in India with a nationwide presence.
2) Asset-Light Expansion: The company continues to expand through acquisitions and operational management contracts rather than relying solely on greenfield projects.
3) Structural Healthcare Growth Story: Rising healthcare spending, increasing insurance penetration, ageing demographics, and growing demand for quality healthcare continue to support long-term growth prospects.
4) Diagnostics + Hospitals Synergy: The combination of hospitals and diagnostics creates cross-selling opportunities and recurring revenue streams.

 # Fortis Healthcare reported a robust Q4 Fy26:

Revenue: ₹2,364.7 crore (\(284\) million), up 17.8% YoY.

Net Profit (PAT): ₹271.2 crore (\(32.5\) million), jumping 44.2% YoY.

Operating EBITDA: ₹532.3 crore (\(63.9\) million), a 22.2% increase YoY.

EBITDA Margins: Expanded to 22.5% from 21.7% in Q4 FY25

 # Growth Drivers

Expansion of bed capacity across existing hospitals. | Rising occupancy levels and higher average revenue per occupied bed (ARPOB). | Growth of diagnostics business. | Acquisitions in key metro markets. | Increasing medical tourism inflows. | Higher penetration of health insurance.

 # Key Risks

High competition from hospital chains such as Apollo Hospitals Enterprise, Max Healthcare Institute and Manipal Hospitals. | Regulatory controls on healthcare pricing. | Rising manpower and operating costs. | Premium valuation relative to historical averages.

 # Gyan Mantra: "Healthcare is not a cyclical story; it is a structural story. The real winners are often those who keep adding beds, patients, and trust.

 # Preferred trade on Fortis Healthcare: The firm represents a high-quality healthcare play riding on India's long-term healthcare demand story. The combination of hospitals, diagnostics, expanding capacity, and a strong national brand positions the company well for sustained earnings growth over the next several years.

Look to buy at CMP, and on dips between 880-900 zone, targeting 993/1031, and then aggressive targets at psychological 1150 mark. Stop below 839. Holding Period 9-12 Months.

Mehta Equities

903 Lodha Supremus, Dr. E Moses Road, Worli Naka, Mumbai - 400 018 Board: +91-22-61507100/101 Fax: +91-22-61507102